Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

doi:10.1158/1078-0432.CCR-16-0630

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2016

Cea Michele, Cagnetta Antonia, Acharya Chirag, Acharya Prakrati, Tai Yu-Tzu, Yang Cao, Lovera Davide, Soncini Debora, Miglino Maurizio, Fraternali-Orcioni Giulio, Mastracci Luca, Nencioni Alessio, Montecucco Fabrizio, Monacelli Fiammetta, Ballestrero Alberto, Hideshima Teru, Chauhan Dharminder, Gobbi Marco, Lemoli Roberto M, Munshi Nikhil, Treon Steven P, Anderson Kenneth C

Abstract excerpt

PURPOSE: Nicotinamide phosphoribosyltransferase (Nampt) regulates intracellular NAD+ pool and is highly expressed in a number of malignancies. FK866, a selective inhibitor of Nampt, depletes intracellular NAD+ levels, thereby blocking cellular metabolism and triggering sensitization to other drugs and cell death. Here we characterized the antitumor effects of Nampt inhibition in Waldenström macroglobulinemia....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Myeloid Differentiation Factor 88

Share to Nicotinamide Phosphoribosyltransferase

Share to Piperidines

Share to Poly(ADP-ribose) Polymerases

Share to Receptors, CXCR4

Share to Waldenstrom Macroglobulinemia

Source

Open in PubMed Open full text

Identifiers

PMID: 27287071
DOI: 10.1158/1078-0432.CCR-16-0630
PMCID: PMC5771267

Genes

BTK
CXCR4
MYD88
NAMPT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.PMID 27287071Read ↗

Emerging drugs for the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.Semantic proximity Read ↗

Intracellular NAD<sup>+</sup>depletion induces autophagic death in multiple myeloma cellsSemantic proximity Read ↗

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.Semantic proximity Read ↗

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaSemantic proximity Read ↗

Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.Semantic proximity Read ↗

Advances in Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.